Immix Biopharma, Inc.

Immix Biopharma, Inc.

NNASDAQ:IMMX
7.48
USD
-0.36
(-4.59%)
-0.84EPS
737.53MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of June 30, 2026, Immix Biopharma, Inc. carries a market capitalization of 737.53M, placing it among publicly traded companies globally. Its enterprise value stands at 506.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap737.53M
Enterprise Value506.43M

Important Dates

Immix Biopharma, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, Immix Biopharma, Inc. has 71.54M shares outstanding.

Shares Outstanding71.54M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio3.22
P/TBV Ratio3.22
P/FCF Ratio-12.49
P/OCF Ratio-12.68

Financial Position

As of June 30, 2026, Immix Biopharma, Inc. maintains a current ratio of 25.13, meaning it holds 25.1x the short-term assets needed to cover near-term liabilities.

Current Ratio25.13
Quick Ratio24.95
Debt / Equity0.44
Debt / EBITDA-0.02

Financial Efficiency

Over the twelve months ended June 30, 2026, Immix Biopharma, Inc. posted a negative return on equity (ROE) of -34.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.34, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-34.18
Return on Assets (ROA)-31.34
Employee Count21.00

Taxes

USD

Over the twelve months ended June 30, 2026, Immix Biopharma, Inc. recorded 33,310.00 in income tax expense. The company reported a pretax loss of -39.88M and -39.92M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax33,310.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Immix Biopharma, Inc.'s stock has gained approximately 77.67% over the past 52 weeks. The 50-day moving average sits at 9.69, while the 200-day moving average is 9.62.

52-Week Price Change77.67%
50-Day Moving Average9.69
200-Day Moving Average9.62

Income Statement

USD

Over the twelve months ended June 30, 2026, Immix Biopharma, Inc. generated - - in revenue and converted that into -39.92M in net income, yielding earnings per share of -0.84. EBITDA reached -41.33M, while operating income came in at -41.82M.

Operating Income-41.82M
Pretax Income-39.88M
Net Income-39.92M
EBITDA-41.33M
EBIT-41.82M
Earnings Per Share (EPS)-0.84

Balance Sheet

USD

As of June 30, 2026, Immix Biopharma, Inc. holds 232.11M in cash and equivalents against 1.00M in total debt, resulting in a net debt position of -225.49M. Total book value stands at 228.92M, with working capital of 224.49M providing operational flexibility.

Cash & Cash Equivalents232.11M
Total Debt1.00M
Net Debt-225.49M
Equity (Book Value)228.92M
Book Value Per Share3.20
Working Capital224.49M

Cash Flow

USD

Immix Biopharma, Inc. produced -38.50M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -591,111.00 in capital expenditures, free cash flow totaled -39.09M - equivalent to -0.83 per share.

Operating Cash Flow-38.50M
Capital Expenditures-591,111.00
Free Cash Flow-39.09M
FCF Per Share-0.83

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -35.46, meaning Immix Biopharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-35.46
FCF Yield-8.01

Scores

As of June 30, 2026, Immix Biopharma, Inc. has an Altman Z-Score of 43.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score43.23